346 related articles for article (PubMed ID: 17494863)
1. Mechanisms responsible for the enhanced antinociceptive effects of micro-opioid receptor agonists in the rostral ventromedial medulla of male rats with persistent inflammatory pain.
Sykes KT; White SR; Hurley RW; Mizoguchi H; Tseng LF; Hammond DL
J Pharmacol Exp Ther; 2007 Aug; 322(2):813-21. PubMed ID: 17494863
[TBL] [Abstract][Full Text] [Related]
2. The analgesic effects of supraspinal mu and delta opioid receptor agonists are potentiated during persistent inflammation.
Hurley RW; Hammond DL
J Neurosci; 2000 Feb; 20(3):1249-59. PubMed ID: 10648729
[TBL] [Abstract][Full Text] [Related]
3. Spinal pharmacology of antinociception produced by microinjection of mu or delta opioid receptor agonists in the ventromedial medulla of the rat.
Hurley RW; Banfor P; Hammond DL
Neuroscience; 2003; 118(3):789-96. PubMed ID: 12710986
[TBL] [Abstract][Full Text] [Related]
4. Contribution of endogenous enkephalins to the enhanced analgesic effects of supraspinal mu opioid receptor agonists after inflammatory injury.
Hurley RW; Hammond DL
J Neurosci; 2001 Apr; 21(7):2536-45. PubMed ID: 11264327
[TBL] [Abstract][Full Text] [Related]
5. Persistent inflammatory pain decreases the antinociceptive effects of the mu opioid receptor agonist DAMGO in the locus coeruleus of male rats.
Jongeling AC; Johns ME; Murphy AZ; Hammond DL
Neuropharmacology; 2009; 56(6-7):1017-26. PubMed ID: 19265713
[TBL] [Abstract][Full Text] [Related]
6. delta-Opioid receptor agonists produce antinociception and [35S]GTPgammaS binding in mu receptor knockout mice.
Hosohata Y; Vanderah TW; Burkey TH; Ossipov MH; Kovelowski CJ; Sora I; Uhl GR; Zhang X; Rice KC; Roeske WR; Hruby VJ; Yamamura HI; Lai J; Porreca F
Eur J Pharmacol; 2000 Feb; 388(3):241-8. PubMed ID: 10675732
[TBL] [Abstract][Full Text] [Related]
7. The spinal antinociceptive effects of endomorphins in rats: behavioral and G protein functional studies.
Xie H; Woods JH; Traynor JR; Ko MC
Anesth Analg; 2008 Jun; 106(6):1873-81. PubMed ID: 18499626
[TBL] [Abstract][Full Text] [Related]
8. Effects of a mu-opioid receptor agonist on G-protein activation in streptozotocin-induced diabetic mice.
Ohsawa M; Mizoguchi H; Narita M; Kamei J; Nagase H; Tseng LF
Eur J Pharmacol; 2000 Jul; 401(1):55-8. PubMed ID: 10915837
[TBL] [Abstract][Full Text] [Related]
9. Region-dependent G-protein activation by mu-, delta 1- and delta 2-opioid receptor agonists in the brain: comparison between the midbrain and forebrain.
Tsuji M; Narita M; Mizoguchi H; Narita M; Ohsawa M; Kamei J; Nagase H; Takeda H; Matsumiya T; Tseng LF
Life Sci; 1999; 65(16):PL233-9. PubMed ID: 10573190
[TBL] [Abstract][Full Text] [Related]
10. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
11. Highly delta selective antagonists in the RVM attenuate the antinociceptive effect of PAG DAMGO.
Hirakawa N; Tershner SA; Fields HL
Neuroreport; 1999 Oct; 10(15):3125-9. PubMed ID: 10574547
[TBL] [Abstract][Full Text] [Related]
12. Heterologous mu-opioid receptor adaptation by repeated stimulation of kappa-opioid receptor: up-regulation of G-protein activation and antinociception.
Narita M; Khotib J; Suzuki M; Ozaki S; Yajima Y; Suzuki T
J Neurochem; 2003 Jun; 85(5):1171-9. PubMed ID: 12753076
[TBL] [Abstract][Full Text] [Related]
13. Involvement of spinal protein kinase Cgamma in the attenuation of opioid mu-receptor-mediated G-protein activation after chronic intrathecal administration of [D-Ala2,N-MePhe4,Gly-Ol(5)]enkephalin.
Narita M; Mizoguchi H; Narita M; Nagase H; Suzuki T; Tseng LF
J Neurosci; 2001 Jun; 21(11):3715-20. PubMed ID: 11356858
[TBL] [Abstract][Full Text] [Related]
14. Cellular basis for opioid potentiation in the rostral ventromedial medulla of rats with persistent inflammatory nociception.
Zhang L; Hammond DL
Pain; 2010 Apr; 149(1):107-116. PubMed ID: 20172653
[TBL] [Abstract][Full Text] [Related]
15. Blockade of opioid receptors in rostral ventral medulla prevents antihyperalgesia produced by transcutaneous electrical nerve stimulation (TENS).
Kalra A; Urban MO; Sluka KA
J Pharmacol Exp Ther; 2001 Jul; 298(1):257-63. PubMed ID: 11408550
[TBL] [Abstract][Full Text] [Related]
16. Inflammation-induced changes in rostral ventromedial medulla mu and kappa opioid receptor mediated antinociception.
Schepers RJ; Mahoney JL; Shippenberg TS
Pain; 2008 Jun; 136(3):320-330. PubMed ID: 17764840
[TBL] [Abstract][Full Text] [Related]
17. Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.
Melkes B; Hejnova L; Novotny J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1289-1300. PubMed ID: 27600870
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo delta opioid receptor autoradiography: CNS receptor occupancy of two novel compounds over their antihyperalgesic dose range.
Codd EE; Ma J; Zhang SP; Stone DJ; Colburn RW; Brandt MR; Chevalier KM; Zhu Y; Peng S; Cai C; Acton PD; Flores CM
Pharmacol Biochem Behav; 2010 Aug; 96(2):130-5. PubMed ID: 20438745
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of intrathecally administered delta and mu opioid receptor agonists on formalin-evoked nociception and on the expression of Fos-like immunoreactivity in the spinal cord of the rat.
Hammond DL; Wang H; Nakashima N; Basbaum AI
J Pharmacol Exp Ther; 1998 Jan; 284(1):378-87. PubMed ID: 9435201
[TBL] [Abstract][Full Text] [Related]
20. Loss of mu-opioid receptor-mediated G-protein activation in the pons/medulla of mice lacking the exons 2 and 3 of mu-opioid receptor gene.
Mizoguchi H; Wu HE; Narita M; Loh HH; Nagase H; Tseng LF
Neurosci Lett; 2002 Dec; 335(2):91-4. PubMed ID: 12459506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
